Press Releases Events & Presentations Press Releases Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 Sep 10, 2026 Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference View HTML PDF Version Sep 08, 2026 Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program View HTML PDF Version Aug 13, 2026 Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates View HTML PDF Version May 28, 2026 Assembly Biosciences Announces Upcoming Investor Conference Presentations View HTML PDF Version May 26, 2026 Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares View HTML PDF Version May 22, 2026 Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants View HTML PDF Version May 22, 2026 Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases View HTML PDF Version May 13, 2026 Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 View HTML PDF Version May 11, 2026 Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference View HTML PDF Version May 07, 2026 Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights View HTML PDF Version Pagination Current page 1 Page 2 Next page next › Last page last » Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Press Releases Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 Sep 10, 2026 Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference View HTML PDF Version Sep 08, 2026 Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program View HTML PDF Version Aug 13, 2026 Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates View HTML PDF Version May 28, 2026 Assembly Biosciences Announces Upcoming Investor Conference Presentations View HTML PDF Version May 26, 2026 Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares View HTML PDF Version May 22, 2026 Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants View HTML PDF Version May 22, 2026 Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases View HTML PDF Version May 13, 2026 Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 View HTML PDF Version May 11, 2026 Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference View HTML PDF Version May 07, 2026 Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights View HTML PDF Version Pagination Current page 1 Page 2 Next page next › Last page last »
